Table 1.
Demographic and clinical characteristics by group
| Demographic/clinical variable | R | NR | ||||
| N | Mean/ratio | SD | N | Mean/ratio | SD | |
| Age | 54 | 29.52 | 9.36 | 52 | 29.99 | 8.50 |
| Gender (male:female) | 54 | 46:8 | – | 52 | 43:9 | – |
| Age of illness onset | 53 | 26.10 | 6.53 | 50 | 25.31 | 5.93 |
| Illness duration since first antipsychotic (years) | 53 | 3.71 | 6.87 | 50 | 5.03 | 5.79 |
| Duration from first psychotic symptom (years) | 54 | 4.81 | 7.53 | 52 | 5.50 | 6.13 |
| Duration from first contact with mental health services (years) | 54 | 4.04 | 7.49 | 52 | 5.40 | 6.34 |
| Full time education (years) | 53 | 13.09 | 2.37 | 50 | 12.88 | 2.75 |
| Chlorpromazine equivalents (mg/day) | 53 | 305.45 | 146.86 | 52 | 343.73 | 202.83 |
| PANSS positive score | 54 | 12.24 | 3.40 | 42 | 22.65 | 3.54 |
| PANSS negative score | 54 | 13.82 | 3.38 | 52 | 20.96 | 4.56 |
| PANSS total score | 54 | 53.46 | 7.91 | 52 | 87.29 | 9.30 |
| CGI positive symptoms score | 53 | 3.26 | 0.76 | 52 | 5.50 | 0.10 |
| CGI negative symptoms score | 53 | 3.21 | 0.86 | 52 | 4.88 | 1.04 |
| CGI cognitive symptoms score | 53 | 3.08 | 0.83 | 52 | 4.83 | 1.22 |
| CGI overall severity | 53 | 3.42 | 0.75 | 52 | 5.48 | 0.58 |
| Antipsychotic at assessment | 54 | Amisulpride=3 Aripiprazole=13 Clopixol=2 Haloperidol=1 Olanzapine=19 Quetiapine=4 Risperidone=9 Flupentixol=1 Paliperidone=2 |
– | 52 | Amisulpride=8 Aripiprazole=10 Clopixol=1 Haloperidol=2 Olanzapine=7 Quetiapine=9 Risperidone=6 Flupentixol=1 Paliperidone=6 Zuclopenthixol acetate=1 |
– |
CGI, Clinical Global Impression; NR, antipsychotic non-responder; PANSS, Positive and Negative Syndrome Scale; R, antipsychotic responder.